Prosecution Insights
Last updated: August 14, 2026
Application No. 17/777,027

IMIDAZOPYRIDINE-BASED ARYLAMINE COMPOUND AND USE THEREOF

Non-Final OA §112
Filed
May 14, 2022
Priority
Dec 11, 2019 — CN 201911268938.0 +1 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Guangdong Aglaia Optoelectronic Materials Co. Ltd.
OA Round
3 (Non-Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
835 granted / 1125 resolved
+14.2% vs TC avg
Strong +30% interview lift
Without
With
+30.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
75 currently pending
Career history
1178
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
20.3%
-19.7% vs TC avg
§112
49.8%
+9.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1125 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/1/2026 has been entered. Status of Claims Claims 5-7,9,14-16, and 19-22 are pending in the instant application. Claims 21-22 are new claims and drawn to nonelected subject matter. Thus claims 6, 7, 15, 16, and 19-22 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 5, 9, and 14 is contained herein. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 1/30/2026 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 4/1/2026. New Objections and Rejections Claim Objections Claims 5, 9, and 14 are objected to because the instant claims possess non-elected subject matter. Applicant elected group I without traverse, drawn to compounds of the general formula I. However as stated in the previous office action, the claims embrace species and subject matter not represented by the originally presented subject matter. Recall that Applicant elected the following chemical formula for formula I: PNG media_image1.png 750 802 media_image1.png Greyscale . The latter may consist of compounds wherein n = 1 (a monomer) or 2 (a symmetrical dimer where there is a constant repeat of a monomer). The examiner assumes that variable “B” is the linking moiety. Applicant’s elected species appears to be representative of the subject matter wherein n = 2: PNG media_image2.png 164 400 media_image2.png Greyscale . However the species in claim 9 for example have a different scaffold when n = 2 and are not symmetrical wherein the species have an extra linking moiety or lacks the other moiety as required by formula I: PNG media_image3.png 260 940 media_image3.png Greyscale . Additionally these species are not embraced by formula I wherein n = 1 as well. Again the examiner assumes that the linking moiety used to connect to the other monomer is variable “B” (appears to be situated outside the parenthesis). Thus these species appear to not be embraced by the originally presented formula I. Note that variable B is defined as one singular cyclic moiety with varying carbon sizes. Additionally there is no guidance in the specification to suggest that these definitions may differ from that recognized in the art as well. Thus the examiner has to use the most reasonable interpretation where these species are not embraced by the formula I presented initially. Furthermore the language in amended claim 5 is not commensurate with what was presented in the original formula. The examiner compares the amended definition for variable Ar1 for example which may be a substituted or unsubstituted C3-C30 aliphatic ring. When comparing with variable B in what was described previously in the original claims the cycloalkyl group was stated to be unsubstituted. Thus the scope is broader now in the instant claims. See variable R1 now in the instant claims which corresponds to Ar1 in the original claims. Variable R1 may be selected from C2-C28 heteroarylene now which is broader than Ar1 in the original formula (C6-C60 heteroaryl). Lastly, the amended claims specify that R1 is connected to the fused ring (imidazopyridine) where the original claims do not provide this possibility based on the “substitution” definition (lacks any heteroaryl as a potential substituent). Thus the examiner objects to this language and suggests amending the claims to be representative of the originally presented subject matter. Correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5 and 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. In claim 5, the language “one or more carbon atoms in heteroalkylene” is considered indefinite since there is no prior recitation of “heteroalkylene” in any of the variable definitions in this claim. Thus the scope of the claim and claims dependent on it are indefinite. Correction is required. Conclusion Claims 5 and 14 are rejected. Claim 9 is objected to. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN MCDOWELL/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

May 14, 2022
Application Filed
Aug 21, 2025
Non-Final Rejection mailed — §112
Nov 06, 2025
Response Filed
Jan 30, 2026
Final Rejection mailed — §112
Apr 01, 2026
Request for Continued Examination
Apr 03, 2026
Response after Non-Final Action
Jun 08, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703694
PYRAZOLE CARBOXYLATE ESTER COMPOUND AND USE THEREOF
3y 11m to grant Granted Aug 11, 2026
Patent 12698283
QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS, AND METHODS OF USE THEREOF
3y 7m to grant Granted Aug 04, 2026
Patent 12691129
USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES
3y 11m to grant Granted Jul 28, 2026
Patent 12673920
INHIBITORS OF NLRP3 INFLAMMASOME
3y 1m to grant Granted Jul 07, 2026
Patent 12667101
PICOLINAMIDE DERIVATIVES USEFUL AS AGRICULTURAL FUNGICIDES
4y 5m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.4%)
2y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1125 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month